Peninsula biotech eyes drug launch after winning FDA approval

Relypsa Inc. won its first drug approval Wednesday as the Food and Drug Administration approved its treatment for potentially fatal levels of potassium in chronic kidney disease patients. The drug, for which the Redwood City company (NASDAQ: RLYP) hadn't announced a price as of late Wednesday afternoon, will carry a "boxed warning" because it could cause other oral drugs to be less effective. A Relypsa spokesman said the company would discuss pricing on a conference call Thursday morning. Pricing…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news